A compound of formula: in which: Y at each occurrence is independently selected from N and CH; Y 1 is selected from N and CR 5; wherein R 5 is selected from hydrogen, methoxy and imidazolyl; wherein said imidazolyl is unsubstituted or substituted with methyl; R 1 is selected from pyrazolyl, thiazolyl, pyrrolyl, imidazolyl, isoxazolyl, furanyl and thienyl; wherein said pyrazolyl, thiazolyl, pyrrolyl, imidazolyl, isoxazolyl, furanyl or thienyl of R 1 is unsubstituted or substituted with 1 to 3 R 6 groups; R 2 is selected from pyrrolidinyl, piperidinyl, azetidinyl, morpholino, piperazinyl, 2-oxa-6-azaspiro[3.4]-octanyl, 3-azabicyclo[3.1.0]hexan-3-yl, pyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl, hexahydropyrrolo[3,4-c]pyrrolyl, 6-oxo-2,7-diazaspiro[4.4]-nonanyl, 1H-pyrrolo[3,4-c]pyridinyl, 1,4-oxazepan-4-yl, 2-oxooxazolidinyl, 1,4-diazepanyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, 3,8-dioxa-10-azabicyclo[4.3.1]decanyl, -OR 5b and -NR 5,R 5b; wherein said piperidinyl, azetidinyl, morpholino, piperazinyl, 1,4-oxazepan-4-yl, pyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl, 2-oxa-6-azaspiro[3.4]-octanyl, 3-azabicyclo[3.1.0]hexan-3-yl, hexahydropyrrolo[3,4-c]pyrrolyl, 6-oxo-2,7-diazaspiro[4.4]-nonanyl, 1H-pyrrolo[3,4-c]pyridinyl, 2-oxooxazolidinyl, 1,4-diazepanyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, or 3,8-dioxa-10-azabicyclo[4.3.1]decanyl of R 2 is unsubstituted or substituted with 1 to 3 R 7 groups; wherein said pyrrolidinyl of R 2 is unsubstituted or substituted with 2 or 3 R 7 groups; R 3 is selected from hydrogen and halo; R 4 is selected from -SF 5 and -Y 2 -CF 2 -Y 3; R 5a is selected from hydrogen and C 1-4 alkyl; R 5b is selected from C 1-4 alkyl and tetrahydro-2H-pyran-4-yl; wherein said alkyl of R 5b is unsubstituted or substituted with 1 to 3 groups independently selected from hydroxy and dimethyl-amino; R 6 at each occurrence is independently selected from hydrogen, hydroxy, methyl, hydroxy, methoxy, cyano, trifluoromethyl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl, cyclopropyl and dimethyl-amino-carbonyl; R 7 at each occurrence is independently selected from hydroxy, methyl, halo, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, 2-amino-3-methylbutanoyl)oxy, carboxy, methoxycarbonyl, phosphonooxy, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form a ring selected from cyclopropyl, azetidin-3-yl and 3-azabicyclo[3.1.0]hexan-3-yl; Y 2 is selected from CF 2, O and S 0-2; and Y 3 is seleectd from hydrogen, halo, methyl, difluoromethyl and trifluoromethyl; or the pharmaceutically acceptable salts thereof. Y at each occurrence is independently selected from N and CH; Y 1 is selected from N and CR 5; wherein R 5 is selected from hydrogen, methoxy and imidazolyl; wherein said imidazolyl is unsubstituted or substituted with methyl; R 1 is selected from pyrazolyl, thiazolyl, pyrrolyl, imidazolyl, isoxazolyl, furanyl and thienyl; wherein said pyrazolyl, thiazolyl, pyrrolyl, imidazolyl, isoxazolyl, furanyl or thienyl of R 1 is unsubstituted or substituted with 1 to 3 R 6 groups; R 2 is selected from pyrrolidinyl, piperidinyl, azetidinyl, morpholino, piperazinyl, 2-oxa-6-azaspiro[3.4]-octanyl, 3-azabicyclo[3.1.0]hexan-3-yl, pyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl, hexahydropyrrolo[3,4-c]pyrrolyl, 6-oxo-2,7-diazaspiro[4.4]-nonanyl, 1H-pyrrolo[3,4-c]pyridinyl, 1,4-oxazepan-4-yl, 2-oxooxazolidinyl, 1,4-diazepanyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, 3,8-dioxa-10-azabicyclo[4.3.1]decanyl, -OR 5b and -NR 5,R 5b; wherein said piperidinyl, azetidinyl, morpholino, piperazinyl, 1,4-oxazepan-4-yl, pyrrolo[3,4-c]pyrazol-5(1H,4H,6H)-yl, 2-oxa-6-azaspiro[3.4]-octanyl, 3-azabicyclo[3.1.0]hexan-3-yl, hexahydropyrrolo[3,4-c]pyrrolyl, 6-oxo-2,7-diazaspiro[4.4]-nonanyl, 1H-pyrrolo[3,4-c]pyridinyl, 2-oxooxazolidinyl, 1,4-diazepanyl, tetrahydro-2H-pyranyl, 3,6-dihydro-2H-pyranyl, or 3,8-dioxa-10-azabicyclo[4.3.1]decanyl of R 2 is unsubstituted or substituted with 1 to 3 R 7 groups; wherein said pyrrolidinyl of R 2 is unsubstituted or substituted with 2 or 3 R 7 groups; R 3 is selected from hydrogen and halo; R 4 is selected from -SF 5 and -Y 2 -CF 2 -Y 3; R 5a is selected from hydrogen and C 1-4 alkyl; R 5b is selected from C 1-4 alkyl and tetrahydro-2H-pyran-4-yl; wherein said alkyl of R 5b is unsubstituted or substituted with 1 to 3 groups independently selected from hydroxy and dimethyl-amino; R 6 at each occurrence is independently selected from hydrogen, hydroxy, methyl, hydroxy, methoxy, cyano, trifluoromethyl, hydroxy-methyl, halo, amino, fluoro-ethyl, ethyl, cyclopropyl and dimethyl-amino-carbonyl; R 7 at each occurrence is independently selected from hydroxy, methyl, halo, methoxy, hydroxy-methyl, amino, methyl-amino, amino-methyl, trifluoromethyl, 2-hydroxypropan-2-yl, methyl-carbonyl-amino, dimethyl-amino, 2-amino-3-methylbutanoyl)oxy, carboxy, methoxycarbonyl, phosphonooxy, cyano and amino-carbonyl; or two R 7 groups combine with the atom to which they are attached to form a ring selected from cyclopropyl, azetidin-3-yl and 3-azabicyclo[3.1.0]hexan-3-yl; Y 2 is selected from CF 2, O and S 0-2; and Y 3 is seleectd from hydrogen, halo, methyl, difluoromethyl and trifluoromethyl; or the pharmaceutically acceptable salts thereof.